Founded in 2014 in San Diego, Capella Therapeutics is focused on the discovery and development of small molecule drugs to treat cancer and inflammatory diseases. 

Capella Therapeutics was founded by Yun Long, Ph.D., a successful medicinal chemist with biotech experiences at Ligand, Galapagos/Biofocus, Nitto Denko Technology, GNF, Vertex, and Well Spring Biosciences. Dr. Long encouraged Alan Lewis, Ph.D.,  David Anderson, Ph.D. and Tony Hunter Ph.D. to join him to further develop the company. Members of this team have successfully developed numerous oncology and anti-inflammatory drugs from concept to market. They all previously worked closely together at Signal Pharmaceuticals and the Signal Division of Celgene.  Later on, Dr. Daniel Von Hoff  and Dr. Robert Wild, both of whom have deep experience in oncology, joined Capella Therapeutics.